V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310003330 | 310001403 | 1.7 | 90.85 | Palliative (P) | 2018-04-23 | 2018-05-24 | PEMBROLIZUMAB | 02 | Y | 310017713 | PEMBROLIZUMAB |
| 310003331 | 310001404 | 1.81 | 86.5 | Palliative (P) | 2016-08-22 | 2016-08-22 | Doxorubicin 75mg/m2 | 2 | null | 310017716 | DOXORUBICIN |
| 310003332 | 310001404 | null | 93 | Palliative (P) | 2015-07-06 | 2015-07-08 | PEMBROLIZUMAB | N | N | 310017716 | PEMBROLIZUMAB |
| 310003333 | 310001405 | 1.66 | 70 | Palliative (P) | 2016-09-03 | 2016-09-06 | PEMBROLIZUMAB | 02 | N | 310017720 | PEMBROLIZUMAB |
| 310003334 | 310001405 | null | 73.9 | Adjuvant (A) | 2016-12-04 | 2016-12-09 | Retinoblastoma JOE | N | N | 310017720 | CEV |
| 310003335 | 310001405 | 1.85 | null | Palliative (P) | 2016-07-30 | 2016-08-14 | CISPLATIN + GEMCITABINE | N | N | 310017720 | CISPLATIN + GEMCITABINE |
| 310003336 | 310001406 | 1.75 | 67.7 | Disease modification (D) | 2014-06-25 | 2014-07-16 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 310017726 | CISPLATIN + GEMCITABINE |
| 310003338 | 310001407 | null | 60.4 | Curative (C) | 2015-07-12 | 2015-07-12 | Retinoblastoma JOE | N | N | 310017730 | CEV |
| 310003339 | 310006589 | 1.64 | 53.9 | Palliative (P) | 2018-12-18 | 2018-12-19 | Ipilimumab | 2 | N | 310017733 | IPILIMUMAB |
| 310003340 | 310001408 | 1.64 | 70 | Palliative (P) | 2016-03-11 | 2016-03-22 | CARBOPLATIN + ETOPOSIDE | 02 | N | 310017735 | CARBOPLATIN + ETOPOSIDE |
| 310003341 | 310001409 | 1.8 | 80.8 | Palliative (P) | 2017-08-12 | 2017-08-12 | Ipilimumab | 02 | N | 310017744 | IPILIMUMAB |
| 310003342 | 310001410 | 1.62 | 83.4 | Disease modification (D) | 2016-04-19 | 2016-05-10 | CHOP R - 21 days | 02 | N | 310017745 | CHOP R |
| 310003343 | 310001410 | 1.58 | null | Palliative (P) | 2017-12-26 | 2018-01-08 | PEMBROLIZUMAB | 02 | N | 310017745 | PEMBROLIZUMAB |
| 310003344 | 310001410 | 1.77 | 82.4 | Curative (C) | 2013-08-26 | 2013-09-02 | CHOP R - 21 days | 2 | N | 310017745 | CHOP R |
| 310003345 | 310001410 | 1.7 | 80 | Not known (9) | 2015-02-15 | 2015-02-15 | Trial Unspecified | Y | N | 310017745 | TRIAL |
| 310003346 | 310001411 | 0 | 72.8 | Adjuvant (A) | 2016-12-22 | 2017-01-06 | Retinoblastoma JOE | N | N | 310017762 | CEV |
| 310003347 | 310006591 | 1.8 | 85.75 | Palliative (P) | 2014-05-10 | 2014-05-18 | PEMBROLIZUMAB | 02 | N | 310017765 | PEMBROLIZUMAB |
| 310003348 | 310009037 | null | null | null | 2016-12-08 | 2016-12-14 | Retinoblastoma JOE | N | N | 310017766 | CEV |
| 310003349 | 310001412 | null | null | Curative (C) | 2017-02-18 | 2017-02-26 | CHOP R - 21 days | N | N | 310017768 | CHOP R |
| 310003350 | 310006592 | 1.63 | 55 | Adjuvant (A) | 2014-05-21 | 2015-06-03 | Trial Unspecified | 01 | N | 310017775 | TRIAL |
| 310003351 | 310001413 | null | 88.1 | null | 2016-10-08 | 2016-10-13 | PEMBROLIZUMAB | 02 | N | 310017776 | PEMBROLIZUMAB |
| 310003352 | 310006593 | 1.69 | 65.1 | Palliative (P) | 2015-08-25 | 2015-08-26 | CISPLATIN + GEMCITABINE | 2 | N | 310017777 | CISPLATIN + GEMCITABINE |
| 310003353 | 310006593 | 1.75 | 83 | null | 2016-05-07 | 2016-05-16 | Cisplatin+Gemcitabine (gallbladder) | N | N | 310017777 | CISPLATIN + GEMCITABINE |
| 310003354 | 310001414 | 1.63 | 68.7 | Palliative (P) | 2014-03-28 | 2014-03-28 | Doxorubicin 75mg/m2 | N | null | 310017779 | DOXORUBICIN |
| 310003355 | 310006594 | 1.71 | 97.3 | Palliative (P) | 2010-05-02 | 2015-04-09 | PEMBROLIZUMAB | 02 | N | 310017780 | PEMBROLIZUMAB |
| 310003356 | 310009039 | null | 96.8 | Palliative (P) | 2013-06-27 | 2013-06-28 | CHOP R - 21 days | 02 | N | 310017781 | CHOP R |
| 310003357 | 310009039 | null | 67 | Palliative (P) | 2015-04-08 | 2015-04-08 | Ipilimumab | N | N | 310017781 | IPILIMUMAB |
| 310003358 | 310009039 | 1.64 | 65 | Palliative (P) | 2017-07-19 | 2017-08-02 | CISPLATIN + GEMCITABINE | N | N | 310017781 | CISPLATIN + GEMCITABINE |
| 310003359 | 310009039 | 1.61 | null | Curative (C) | 2014-05-03 | 2014-05-19 | CHOP R - 21 days | 02 | N | 310017781 | CHOP R |
| 310003360 | 310001415 | null | 84.3 | Curative (C) | 2015-04-13 | 2015-04-13 | Cisplatin | 02 | Y | 310017786 | CISPLATIN |
| 310003361 | 310001416 | 1.74 | 110.7 | Not known (9) | 2016-07-06 | 2016-07-17 | Ipilimumab | 02 | N | 310017787 | IPILIMUMAB |
| 310003362 | 310001416 | null | 64.2 | Adjuvant (A) | 2015-04-01 | 2015-05-01 | Cisplatin | N | Y | 310017787 | CISPLATIN |
| 310003363 | 310001416 | 1.62 | null | Palliative (P) | 2013-05-02 | 2013-05-02 | CARBOPLATIN + ETOPOSIDE | N | N | 310017787 | CARBOPLATIN + ETOPOSIDE |
| 310003364 | 310001416 | null | 90 | Palliative (P) | 2014-11-21 | 2014-11-21 | Ipilimumab | 02 | null | 310017787 | IPILIMUMAB |
| 310003365 | 310001416 | 1.83 | null | Adjuvant (A) | 2014-07-08 | 2014-07-23 | CARBOPLATIN + ETOPOSIDE | N | N | 310017787 | CARBOPLATIN + ETOPOSIDE |
| 310003366 | 310001416 | 1.62 | 46.5 | Palliative (P) | 2017-07-02 | 2017-07-06 | Ipilimumab | 2 | N | 310017787 | IPILIMUMAB |
| 310003367 | 310001417 | 1.9 | 85.2 | Curative (C) | 2017-10-25 | 2017-11-20 | CHEMO-T TRIAL | N | N | 310017796 | TRIAL |
| 310003368 | 310001418 | 1.86 | 97.4 | Neo-adjuvant (N) | 2013-10-13 | 2013-10-13 | CISPLATIN + GEMCITABINE | 02 | N | 310017800 | CISPLATIN + GEMCITABINE |
| 310003369 | 310006596 | 1.52 | null | Adjuvant (A) | null | 2013-11-13 | Trial Unspecified | N | Y | 310017801 | TRIAL |
| 310003370 | 310006596 | 1.7 | 89.55 | Adjuvant (A) | 2017-06-17 | 2017-06-25 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 310017801 | CISPLATIN + GEMCITABINE |
| 310003371 | 310010326 | null | 74.7 | Palliative (P) | 2014-11-20 | 2014-11-24 | Ipilimumab | 02 | N | 310017805 | IPILIMUMAB |
| 310003372 | 310001419 | 0.52 | 76.1 | Adjuvant (A) | 2014-10-29 | 2014-11-03 | Retinoblastoma JOE | N | N | 310017807 | CEV |
| 310003373 | 310001420 | null | 76.5 | Curative (C) | 2014-12-14 | 2014-12-15 | Retinoblastoma JOE | N | N | 310017810 | CEV |
| 310003374 | 310006597 | null | 70 | Curative (C) | 2014-06-10 | 2014-06-10 | Trial Unspecified | Y | N | 310017812 | TRIAL |
| 310003375 | 310006597 | 1.61 | 83 | Palliative (P) | 2015-02-12 | 2015-02-12 | Trial Unspecified | Y | N | 310017812 | TRIAL |
| 310003376 | 310006597 | 1.56 | 109.8 | Palliative (P) | 2018-04-28 | 2018-04-28 | Ipilimumab | N | N | 310017812 | IPILIMUMAB |
| 310003377 | 310001421 | 0 | 83.9 | Curative (C) | 2017-01-15 | 2017-01-15 | Retinoblastoma JOE | N | N | 310017819 | CEV |
| 310003378 | 310001421 | 1.74 | 93.8 | Adjuvant (A) | 2013-08-31 | 2013-09-14 | Cisplatin | null | N | 310017819 | CISPLATIN |
| 310003379 | 310001421 | 1.73 | 78.6 | Palliative (P) | 2017-03-17 | 2017-03-17 | Trial Unspecified | 01 | null | 310017819 | TRIAL |
| 310003380 | 310001422 | 1.79 | 70.3 | Palliative (P) | 2013-10-03 | 2013-10-05 | CHEMO-T TRIAL | Y | N | 310017825 | TRIAL |